Evidence map›Paper›PMID 36355658›Full record

ArticlePloS one2022

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion.

Carly A Rodriguez, Sara Lodi, C Robert Horsburgh, Mathieu Bastard, Cathy Hewison, Helena Huerga, Munira Khan, Palwasha Y Khan, Uzma Khan, Lawrence Oyewusi and 3 more

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carly A RodriguezDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0003-0023-2111
Sara LodiDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.
C Robert HorsburghDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Mathieu BastardEpicentre, Paris, France.
Cathy HewisonMédecins Sans Frontières, Paris, France.
Helena HuergaEpicentre, Paris, France.ORCID 0000-0003-0302-9063
Munira KhanTHINK TB & HIV Investigative Network, Durban, South Africa.ORCID 0000-0003-2083-2106
Palwasha Y KhanInteractive Research and Development Global, Singapore, Singapore.
Uzma KhanInteractive Research and Development Global, Singapore, Singapore.
Lawrence OyewusiPartners In Health, Maseru, Lesotho.
Shrivani PadayacheeTHINK TB & HIV Investigative Network, Durban, South Africa.
Carole D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
Molly F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.

Funding

Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methodsR01AI146095 · NIAID · HARVARD MEDICAL SCHOOL · PI FRANKE, MOLLY FORREST · 2020 to 2024
$3.6M
Causal inference for the treatment and management of multidrug-resistant tuberculosisF31AI157333 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RODRIGUEZ, CARLY · 2021 to 2021
$30k
NIAID NIH HHS F31 AI157333NIAID NIH HHS R01 AI146095
6 · The paper itself

Abstract

backgroundConversion of sputum culture from positive to negative for M. tuberculosis is a key indicator of treatment response. An initial positive culture is a pre-requisite to observe conversion. Consequently, patients with a missing or negative initial culture are excluded from analyses of conversion outcomes. To identify the initial, or "baseline" culture, researchers must define a sample collection interval. An interval extending past treatment initiation can increase sample size but may introduce selection bias because patients without a positive pre-treatment culture must survive and remain in care to have a culture in the post-treatment interval.

methodsWe used simulated data and data from the endTB observational cohort to investigate the potential for bias when extending baseline culture intervals past treatment initiation. We evaluated bias in the proportion with six-month conversion.

resultsIn simulation studies, the potential for bias depended on the proportion of patients missing a pre-treatment culture, proportion with conversion, proportion culture positive at treatment initiation, and proportion of patients missing a pre-treatment culture who would have been observed to be culture positive, had they had a culture. In observational data, the maximum potential for bias when reporting the proportion with conversion reached five percentage points in some sites.

conclusionExtending the allowable baseline interval past treatment initiation may introduce selection bias. If investigators choose to extend the baseline collection interval past treatment initiation, the proportion missing a pre-treatment culture and the number of deaths and losses to follow up during the post-treatment allowable interval should be clearly enumerated.

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsCohort StudiesHumansSelection BiasSputumTreatment OutcomeAntitubercular Agents

Identifiers

PMID36355658
PMCPMC9648724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.